This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Company News for Nov 4, 2024
by Zacks Equity Research
Companies in The News Are: XOM,CVX,CAH,CHD
Cardinal Health, Inc. (CAH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
by Zacks Equity Research
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Here's What Key Metrics Tell Us About Cardinal (CAH) Q1 Earnings
by Zacks Equity Research
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 14.63% and 1.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Cardinal (CAH) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Cardinal Health (CAH) closed at $110.87, indicating a -0.02% shift from the previous trading day.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cardinal Health to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth
Cardinal Health (CAH) Stock Moves -0.08%: What You Should Know
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $112.32, representing a -0.08% change from its previous close.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $111.92, denoting a -0.52% change from the preceding trading day.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
by Zacks Equity Research
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
Cardinal Health (CAH) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $111.76, representing a -0.2% change from its previous close.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Cardinal Health (CAH) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $110.33 in the latest trading session, marking a -0.17% move from the prior day.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.